102 related articles for article (PubMed ID: 10798920)
1. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
Droller MJ
J Urol; 2000 May; 163(5):1601. PubMed ID: 10798920
[No Abstract] [Full Text] [Related]
2. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
Oh WK; Manola J; Richie JP; Loughlin KR; Kantoff PW
Cancer; 1999 Oct; 86(7):1329-34. PubMed ID: 10506721
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report.
Lu YM; Chien TM; Lin CH; Chai CY; Huang CN
J Med Case Rep; 2016 Apr; 10():98. PubMed ID: 27091477
[TBL] [Abstract][Full Text] [Related]
4. Cis-platin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract.
Carmichael J; Cornbleet MA; MacDougall RH; Allan SG; Duncan W; Chisholm GD; Smyth JF
Br J Urol; 1985 Jun; 57(3):299-302. PubMed ID: 3873976
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy of colorectal cancer.
Hansen RM
Wis Med J; 1988 May; 87(5):27-9. PubMed ID: 3291406
[No Abstract] [Full Text] [Related]
6. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
Kattan J; Culine S; Theodore C; Droz JP
Cancer Invest; 1995; 13(3):276-9. PubMed ID: 7743380
[TBL] [Abstract][Full Text] [Related]
9. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
[TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Scher HI
J Urol; 1992 Nov; 148(5):1625-6. PubMed ID: 1433578
[No Abstract] [Full Text] [Related]
12. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
Siefker-Radtke AO; Millikan RE; Tu SM; Moore DF; Smith TL; Williams D; Logothetis CJ
J Clin Oncol; 2002 Mar; 20(5):1361-7. PubMed ID: 11870180
[TBL] [Abstract][Full Text] [Related]
14. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin, methotrexate and mitoxantrone in patients with metastatic or advanced urothelial cancer.
Andersen LJ; Sengeløv L; Kamby C; von der Maase H
Acta Oncol; 1998; 37(1):110-2. PubMed ID: 9572664
[No Abstract] [Full Text] [Related]
16. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
Galsky MD; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):30.e15-21. PubMed ID: 23428534
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of metastatic gastric cancer.
Wils J
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():395-8. PubMed ID: 10895185
[No Abstract] [Full Text] [Related]
19. The evolving role of chemotherapy in advanced urothelial cancer.
Calabrò F; Sternberg CN
Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Pu YS; Vogelzang NJ
BJU Int; 2008 Apr; 101(7):795-803. PubMed ID: 18070193
[No Abstract] [Full Text] [Related]
[Next] [New Search]
